Patents by Inventor Jeffrey A. Medin

Jeffrey A. Medin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel In Vitro and In Vivo Enrichment Strategy Targeting Lymphocytes Derived from Vector Transduced HSCS for Therapy of Disorders
    Publication number: 20230332112
    Abstract: The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.
    Type: Application
    Filed: March 7, 2023
    Publication date: October 19, 2023
    Inventors: Jeffrey A. Medin, John F. Dipersio, Murtaza S. Nagree
  • SYSTEM AND METHOD FOR THE DEVELOPMENT OF CD30 BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY OF CD30+ MALIGNANCIES
    Publication number: 20230312738
    Abstract: The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.
    Type: Application
    Filed: April 17, 2023
    Publication date: October 5, 2023
    Inventors: Jeffrey A. Medin, Lawrence G. Lum, Robyn A.A. Oldham, Archana Thakur
  • Multiple Myeloma Mapping and Uses Thereof
    Publication number: 20230280344
    Abstract: The present invention provides methods and kits for detecting and treating multiple myeloma. The methods involve detecting proteins that the inventors have identified as biomarkers of multiple melanoma.
    Type: Application
    Filed: July 15, 2021
    Publication date: September 7, 2023
    Inventors: Jeffrey A. Medin, Robyn A. Oldham, Mary L. Faber, Rebekah L. Gundry
  • Anti-CD30 Antibodies and Methods for Treating CD30+ Cancer
    Publication number: 20230235071
    Abstract: The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.
    Type: Application
    Filed: February 2, 2023
    Publication date: July 27, 2023
    Inventors: Jeffrey A. Medin, Mary L. Faber, Everett R. Tate, Robyn A.A. Oldham
  • Improved Lentiviral Vector Transfer Plasmid and Methods of Use
    Publication number: 20230220419
    Abstract: The present invention provides an improved lentiviral backbone for use in gene therapy.
    Type: Application
    Filed: May 25, 2021
    Publication date: July 13, 2023
    Inventors: Jeffrey A. Medin, William M. McKillop, Kristy J. Gargulak
  • CD30 bispecific antibodies and method of immunotherapy of CD30+ malignancies
    Patent number: 11667721
    Abstract: The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: June 6, 2023
    Assignees: Medical College of Wisconsin, Inc., University of Virginia Patent Foundation
    Inventors: Jeffrey A. Medin, Lawrence G. Lum, Robyn A. A. Oldham, Archana Thakur
  • Recombinant PD-L1 Peptides and Methods of Use
    Publication number: 20230135850
    Abstract: The present disclosure provides soluble mutant PD-L1 peptides, polynucleotides and vectors encoding the peptides, and methods of using the peptides to elicit differentiation of regulatory T cells.
    Type: Application
    Filed: April 14, 2020
    Publication date: May 4, 2023
    Inventors: Kaothara Oluwakemi Adeyanju, Jeffrey A. Medin, Robert Blake Hill, Lawrence G. Lum
  • and enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
    Patent number: 11597917
    Abstract: The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: March 7, 2023
    Assignees: The Medical College of Wisconsin, Inc., University Health Network, Washington University in St. Louis
    Inventors: Jeffrey A. Medin, John F. Dipersio, Murtaza S. Nagree
  • Anti-CD30 antibodies and methods for treating CD30+ cancer
    Patent number: 11584799
    Abstract: The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: February 21, 2023
    Assignees: Medical College of Wisconsin, Inc., University of Virginia Patent Foundation
    Inventors: Jeffrey A. Medin, Mary L. Faber, Everett R. Tate, Robyn A. A. Oldham
  • Improved Alpha-Galactosidase Protein for Enzyme Replacement Therapy (ERT) and Methods of Use
    Publication number: 20220348896
    Abstract: The present disclosure provides less immunogenic mutant ?-galactosidase A protein (?-gal), methods of making and methods of use. The less immunogenic mutant ?-gal of the present invention provides a reduced immune response when administered to a subject.
    Type: Application
    Filed: September 18, 2020
    Publication date: November 3, 2022
    Inventors: Jeffrey A. Medin, Simone Scalia
  • T-Rapa Cells as Novel Effector Cell Type for Chimeric Antigen Receptor Therapy
    Publication number: 20220016167
    Abstract: The present disclosure provides chimeric antigen receptor (CAR)-T-Rapa cells and methods of making and using them. Specifically, methods of producing T-Rapa cells that can express chimeric antigen receptors is provided.
    Type: Application
    Filed: November 27, 2019
    Publication date: January 20, 2022
    Inventors: Jeffrey A. Medin, Robyn A. Oldham, Daniel H. Fowler, Tania Felizardo
  • Use of Lentivector-Transduced T-RAPA Cells for Amelioration of Lysosomal Storage Disorders
    Publication number: 20210322472
    Abstract: The present disclosure provides methods of treating lysosomal storage disorders. The method comprises producing vector-transduced T-Rapa cells that express a transgene of interest and administering the cells to a patient in need thereof.
    Type: Application
    Filed: April 29, 2019
    Publication date: October 21, 2021
    Inventors: Jeffrey A. Medin, Daniel H. Fowler, Murtaza S. Nagree, Tania Felizardo
  • NOVEL IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING LYMPHOCYTES DERIVED FROM VECTOR TRANSDUCED HSCS FOR THERAPY OF DISORDERS
    Publication number: 20200181582
    Abstract: The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.
    Type: Application
    Filed: June 6, 2018
    Publication date: June 11, 2020
    Inventors: Jeffrey A. Medin, John F. Dipersio, Murtaza S. Nagree
  • ANTI-CD30 ANTIBODIES AND METHODS OF USE
    Publication number: 20200095329
    Abstract: The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.
    Type: Application
    Filed: September 24, 2019
    Publication date: March 26, 2020
    Inventors: JEFFREY A. MEDIN, MARY L. FABER, EVERETT R. TATE, ROBYN A.A. OLDHAM
  • SYSTEM AND METHOD FOR THE DEVELOPMENT OF CD30 BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY OF CD30+ MALIGNANCIES
    Publication number: 20200095330
    Abstract: The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.
    Type: Application
    Filed: September 24, 2019
    Publication date: March 26, 2020
    Inventors: Jeffrey A. Medin, Lawrence G. Lum, Robyn A.A. Oldham, Archana Thakur
  • IL-12 IMMUNOTHERAPY FOR CANCER
    Publication number: 20200038457
    Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.
    Type: Application
    Filed: March 19, 2019
    Publication date: February 6, 2020
    Inventors: Jeffrey A. MEDIN, Christopher J. PAIGE
  • IL-12 immunotherapy for cancer
    Patent number: 10258653
    Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: April 16, 2019
    Assignee: University Health Network
    Inventors: Jeffrey A. Medin, Christopher J. Paige
  • Thymidylate kinase fusions and uses thereof
    Patent number: 10137205
    Abstract: The application relates to a composition comprising a stably integrating delivery vector, a modified mammalian thymidylate kinase (tmpk) that increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk, and a detection cassette fused to the tmpk. The application also relates to use of these compositions in methods of treatment of diseases, such as graft versus host disease and cancer.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: November 27, 2018
    Assignee: University Health Network
    Inventors: Jeffrey A. Medin, Sean Devine
  • IL-12 immunotherapy for cancer
    Patent number: 10022405
    Abstract: Compositions and methods far delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: July 17, 2018
    Assignee: University Health Network
    Inventors: Jeffrey A. Medin, Christopher J. Paige
  • IL-12 IMMUNOTHERAPY FOR CANCER
    Publication number: 20170136072
    Abstract: Compositions and methods far delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.
    Type: Application
    Filed: November 22, 2016
    Publication date: May 18, 2017
    Inventors: Jeffrey A. MEDIN, Christopher J. PAIGE